Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This observational study aims to compare the effectiveness of ultrasound-guided erector spinae plane (ESP) block and transcutaneous radiofrequency (RF) treatment in patients with postherpetic neuralgia. Pain intensity and neuropathic pain characteristics will be evaluated using the Visual Analog Scale (VAS) and the Self-Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) score.
Postherpetic neuralgia is a challenging neuropathic pain condition that significantly affects quality of life. In routine clinical practice, patients are treated with either ultrasound-guided erector spinae plane block or transcutaneous radiofrequency therapy based on clinician preference and experience.
This observational study includes patients who have already completed one of these treatments as part of standard care in the Algology Clinic. No randomization or modification of treatment plans was performed for research purposes. Patients will be divided into two cohorts according to the treatment they received. Treatment outcomes will be retrospectively evaluated and compared using VAS and S-LANSS scores before treatment, immediately after treatment, and at 1-month follow-up.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Erector Spinae Plane Block | Patients with postherpetic neuralgia who received ultrasound-guided erector spinae plane block as part of routine clinical care. |
| |
| Transcutaneous Radiofrequency | Patients with postherpetic neuralgia who received transcutaneous radiofrequency treatment applied adjacent to the lesion area as part of routine clinical care |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Erector Spinae Plane Block | Procedure |
|
| Measure | Description | Time Frame |
|---|---|---|
| VAS | Pain intensity assessed by Visual Analog Scale (VAS): is a simple tool used in clinical trials to measure pain intensity. Patients rate their pain on a scale, typically from 0 (no pain) to 10 (worst imaginable pain). It provides a quick, quantitative assessment of subjective pain and is commonly used to evaluate treatment effectiveness before and after intervention. | Baseline, post-procedure 1 month |
| Measure | Description | Time Frame |
|---|---|---|
| S-LANSS | Neuropathic pain characteristics were assessed using the Self-report Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) questionnaire. The S-LANSS is a validated self-administered screening tool consisting of seven items evaluating pain quality and sensory abnormalities, including burning sensation, electric shock-like pain, dysesthesia, and altered skin sensitivity. Total scores range from 0 to 24, with scores ≥12 indicating a probable neuropathic pain component. The questionnaire has demonstrated good sensitivity and specificity for identifying neuropathic pain in both clinical and research settings. |
Not provided
Inclusion Criteria:
Diagnosis of postherpetic neuralgia involving cervical, thoracic, or lumbar regions
Age between 18 and 80 years
Persistent pain despite conservative treatment
Baseline VAS score > 5
Exclusion Criteria:
Ophthalmic or extremity postherpetic neuralgia
Allergy to local anesthetics
Pregnancy
Coagulopathy or use of antiplatelet therapy
Cognitive impairment preventing informed consent
Not provided
Not provided
Patients aged 18 to 80 years diagnosed with postherpetic neuralgia involving cervical, thoracic, or lumbar dermatomes who underwent either ultrasound-guided erector spinae plane block or transcutaneous radiofrequency treatment as part of routine clinical care. Patients were included if they had persistent pain despite conservative treatment and a baseline Visual Analog Scale (VAS) score greater than 5. All treatments were completed prior to study enrollment, and no changes were made to clinical management for research purposes.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| AYSE BETUL ACAR | Contact | +905326685180 | betulbozann@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| AYSE BETUL ACAR | Diskapi TRH | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ayse Betul Acar | Recruiting | Ankara | 06500 | Turkey (Türkiye) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D051474 | Neuralgia, Postherpetic |
| D009437 | Neuralgia |
| D006562 | Herpes Zoster |
| ID | Term |
|---|---|
| D010523 | Peripheral Nervous System Diseases |
| D009468 | Neuromuscular Diseases |
| D009422 | Nervous System Diseases |
| D010146 | Pain |
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| Baseline, post-procedure 1 month |
| D009461 |
| Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D000073618 | Varicella Zoster Virus Infection |
| D006566 | Herpesviridae Infections |
| D004266 | DNA Virus Infections |
| D014777 | Virus Diseases |
| D007239 | Infections |